FDA Issues MDO on 65 "MNGO Disposable Stick" Vapes of Shenzhen YIBAI Technology

Regulations by 2FIRSTS
Apr.16.2024
FDA Issues MDO on 65 "MNGO Disposable Stick" Vapes of Shenzhen YIBAI Technology
FDA issues Marketing Denial Order to China's Yi Bai Technology, banning sale of 65 "MNGO Disposable Stick" e-cigarettes in US.

According to an announcement released by the United States FDA on April 15, the FDA has issued a Marketing Denial Order (MDO) to Shenzhen Yibai Technology Co., Ltd., prohibiting the sale of 65 disposable e-cigarettes named "MNGO Disposable Stick" in the United States. Failure to comply could result in legal action by the FDA against the company.

 

FDA Issues MDO on 65
Announcement | Image source: US FDA

 

The FDA has announced a ban on flavored disposable e-cigarettes, including tobacco, mint, pink lemonade, strawberry mango, watermelon ice, and ice banana flavors, with nicotine concentrations ranging from 2% to 6% for each flavor. According to the 2023 National Youth Tobacco Survey (NYTS), disposable e-cigarettes are the most commonly used device among e-cigarette users, with nearly 90% of users reporting that they use fruit-flavored e-cigarettes.

 

Dr. Brian King, Director of the FDA's Center for Tobacco Products, revealed that data submitted by Yibai Technology in their application indicated that products marketed as "Clear" flavor, claiming to be flavorless or odorless, actually contain flavoring agents or present a minty taste. Based on all evidence, the FDA has determined that these products have distinct flavors.

 

After a multidisciplinary scientific review, the FDA determined that the application materials lacked sufficient evidence to demonstrate that the marketing of the product meets the public health protection standards required by the 2009 Family Smoking Prevention and Tobacco Control Act - especially in terms of product stability, manufacturing processes, design features to prevent product tampering or misuse, and other necessary data. Therefore, the application was not sufficient to prove that flavored e-cigarettes offer additional benefits to adult smokers compared to tobacco-flavored e-cigarettes, such as aiding in quitting smoking completely or significantly reducing cigarette use, thus offsetting the risks they pose to youth.

 

The FDA has announced that it has received 26 million applications for related products, with the majority being e-cigarettes, and has already made decisions on 99% of the applications. Since December 2023, the FDA has issued market denial orders for over 20,000 flavored e-cigarette products, including Shenzhen Yibo Technology's MNGO disposable e-cigarette product.

 

As of now, the FDA has authorized the legal sale of 23 e-cigarette devices and tobacco-flavored e-cigarette products. Information on tobacco products allowed for sale by law can be found in the new tobacco product database established by the FDA.

 

Notice

1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.

2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.

3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.

Copyright

This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.

This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.